Cargando…
Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA
We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identifie...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154139/ https://www.ncbi.nlm.nih.gov/pubmed/30226154 http://dx.doi.org/10.3201/eid2410.180459 |
_version_ | 1783357644507971584 |
---|---|
author | Garfein, Richard S. Liu, Lin Cuevas-Mota, Jazmine Collins, Kelly Muñoz, Fatima Catanzaro, Donald G. Moser, Kathleen Higashi, Julie Al-Samarrai, Teeb Kriner, Paula Vaishampayan, Julie Cepeda, Javier Bulterys, Michelle A. Martin, Natasha K. Rios, Phillip Raab, Fredric |
author_facet | Garfein, Richard S. Liu, Lin Cuevas-Mota, Jazmine Collins, Kelly Muñoz, Fatima Catanzaro, Donald G. Moser, Kathleen Higashi, Julie Al-Samarrai, Teeb Kriner, Paula Vaishampayan, Julie Cepeda, Javier Bulterys, Michelle A. Martin, Natasha K. Rios, Phillip Raab, Fredric |
author_sort | Garfein, Richard S. |
collection | PubMed |
description | We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18–87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%–97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%–89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%–46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT. |
format | Online Article Text |
id | pubmed-6154139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-61541392018-10-01 Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA Garfein, Richard S. Liu, Lin Cuevas-Mota, Jazmine Collins, Kelly Muñoz, Fatima Catanzaro, Donald G. Moser, Kathleen Higashi, Julie Al-Samarrai, Teeb Kriner, Paula Vaishampayan, Julie Cepeda, Javier Bulterys, Michelle A. Martin, Natasha K. Rios, Phillip Raab, Fredric Emerg Infect Dis Research We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18–87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%–97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%–89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%–46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT. Centers for Disease Control and Prevention 2018-10 /pmc/articles/PMC6154139/ /pubmed/30226154 http://dx.doi.org/10.3201/eid2410.180459 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Garfein, Richard S. Liu, Lin Cuevas-Mota, Jazmine Collins, Kelly Muñoz, Fatima Catanzaro, Donald G. Moser, Kathleen Higashi, Julie Al-Samarrai, Teeb Kriner, Paula Vaishampayan, Julie Cepeda, Javier Bulterys, Michelle A. Martin, Natasha K. Rios, Phillip Raab, Fredric Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
title | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
title_full | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
title_fullStr | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
title_full_unstemmed | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
title_short | Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA |
title_sort | tuberculosis treatment monitoring by video directly observed therapy in 5 health districts, california, usa |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154139/ https://www.ncbi.nlm.nih.gov/pubmed/30226154 http://dx.doi.org/10.3201/eid2410.180459 |
work_keys_str_mv | AT garfeinrichards tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT liulin tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT cuevasmotajazmine tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT collinskelly tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT munozfatima tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT catanzarodonaldg tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT moserkathleen tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT higashijulie tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT alsamarraiteeb tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT krinerpaula tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT vaishampayanjulie tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT cepedajavier tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT bulterysmichellea tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT martinnatashak tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT riosphillip tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa AT raabfredric tuberculosistreatmentmonitoringbyvideodirectlyobservedtherapyin5healthdistrictscaliforniausa |